Angiotensin‐Converting Enzyme Inhibitors and Type 2 Diabetic Nephropathy: A Meta‐Analysis

Pharmacotherapy - Tập 23 Số 7 - Trang 909-915 - 2003
Robert A. Hamilton1, Michael P. Kane1, Jason D. Demers2
1Department of Pharmacy Practice, Albany College of Pharmacy, Albany, New York.
2Department of Pharmacy, Albany Medical Center, Albany, New York.

Tóm tắt

Objective. To perform a meta‐analysis on studies evaluating the effect of angiotensin‐converting enzyme (ACE) inhibitors on diabetic nephropathy in patients with type 2 diabetes mellitus.Methods. A computerized literature search was conducted for articles of studies comparing ACE inhibitors with a control in patients with diabetes, in which measurement of albuminuria or proteinuria was an outcome. Each article was abstracted by two of the authors. Data from the articles were presented as geometric or arithmetic means. The data were summarized separately by using standard techniques for meta‐analysis.Main Results. Statistically significant reductions in albuminuria were observed regardless of whether data were described with geometric or arithmetic means. Both were associated with significant heterogeneity. When studies reporting geometric means were stratified and analyzed, the heterogeneity was lost and statistically significant reductions in albuminuria were observed. The same procedure was repeated for studies reporting arithmetic means, but heterogeneity remained.Conclusion. The ACE inhibitors produce statistically significant reductions in albuminuria associated with significant heterogeneity of effect. Stratification reduces the heterogeneity and supports treatment with ACE inhibitors to reduce the progression of nephropathy in patients with type 2 diabetes mellitus.

Từ khóa


Tài liệu tham khảo

U.S. Renal Data System., 2001, USRDS 2001 annual data report

10.1056/NEJMcp011773

American Diabetes Association., 2001, Treatment of hypertension in adults with diabetes, Diabetes Care, 24, S71

National Institutes of Health., 2001, Excerpts from the United States renal data system's 2001 annual data report: atlas of end‐stage renal disease in the United States. Economic costs of end stage renal disease, Am J Kidney Dis, 38, S181

Bohlen L., 1994, Comparative study of the effect of ACE‐inhibitors and other antihypertensive agents on proteinuria in diabetic patients, Am J Hypertens, 7, S84, 10.1093/ajh/7.9.84S

10.7326/0003-4819-118-2-199301150-00009

Bakris G.L., 1991, Renal effects of calcium antagonists in diabetes mellitus: an overview of studies in animal models and in humans, Am J Hypertens, 4, S487, 10.1093/ajh/4.7.487S

10.1046/j.1523-1755.1998.00055.x

10.1001/archinte.1997.00440420033005

10.1056/NEJMoa011161

10.1056/NEJMoa011303

10.1056/NEJMoa011489

10.2337/diacare.25.2007.S85

10.1056/NEJM199311113292004

10.1097/00004872-199612002-00003

10.1002/(SICI)1096-9136(1998120)15:4 <S51::AID-DIA740>3.0.CO;2-Y

10.1016/1056-8727(96)00031-1

Rodby R.A., 1997, Type II diabetic nephropathy: its clinical course and therapeutic implications, Semin Nephrol, 17, 132

10.1097/00004872-199508001-00015

Ruggenenti P., 1996, The renoprotective action of angiotensin‐converting enzyme inhibitors in diabetes, Exp Nephrol, 4, 53

McClave J.T., 1994, Statistics, 967

Petitti D.B., 2000, Meta‐analysis, decision analysis, and cost‐effectiveness analysis: methods for quantitative synthesis in medicine, 306

Ravid M., 1996, Long‐term renoprotective effect of angiotensin‐converting enzyme inhibition in non‐insulin‐dependent diabetes mellitus: a 7‐year follow‐up study, Arch Intern Med, 156, 286, 10.1001/archinte.1996.00440030080010

10.7326/0003-4819-118-8-199304150-00001

10.1038/ki.1996.480

10.1046/j.1523-1755.1998.00083.x

10.1161/01.HYP.19.2_Suppl.II237

10.1159/000188358

10.2337/diabetes.43.9.1108

10.1159/000045163

10.7326/0003-4819-128-12_Part_1-199806150-00004

10.2337/diacare.16.4.597

10.1002/(SICI)1096-9136(199602)13:2<120::AID-DIA6>3.0.CO;2-F

10.1097/00004872-198900076-00153

10.2337/diab.45.2.216

Lebovitz H.E., 1994, Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria, Kidney Int Suppl, 45, S150

10.2337/diacare.23.9.1278

10.2337/diacare.24.2.412

10.2337/diacare.21.4.518

10.1056/NEJM198512263132601

10.1172/JCI112521

10.1038/ki.1989.227

10.1136/bmj.293.6545.471

10.1056/NEJM200109203451209

10.1046/j.1523-1755.2001.0600031131.x

10.2337/diacare.25.2.406

10.7326/0003-4819-131-9-199911020-00005

Molitch M.E., 2003, Diabetic nephropathy, Diabetes Care, 26, S94

Arauz‐Pacheco C., 2003, Treatment of hypertension in adults with diabetes, Diabetes Care, 26, S80

10.1056/NEJM200001203420301

Thông tin
Thông tin xuất bản

Pharmacotherapy

Tập 23 Số 7

909-915

Thông tin tác giả